MOTIVATION LETTER Addiction is a disease of memory. The Conjunctive Consolidation Threshold model I developed and validated as an independent researcher in Lagos addresses this directly by preventing the encoding of reward-memory associations before they become compulsive. My three sole-authored preprints on OSF and Zenodo, including a formal mathematical specification and a Bayesian population dynamics architecture, demonstrate an 85.8 percent reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. A provisional patent on the CCT core architecture is filed for Q3 2026. The Pioneer Innovator Grant from the Novo Nordisk Foundation is the correct vehicle to translate this platform technology into two commercialisation pathways. First, IMPRINT, the addiction-liability screening tool I built, can serve pharmaceutical companies developing therapies for obesity and diabetes, conditions where reward-circuit dysregulation is a known comorbidity and where Novo Nordisk has deep expertise. Second, the CCT model can be deployed as a computational service for personalised addiction risk assessment, addressing the global health burden of substance use disorders in LMICs like Nigeria, where treatment access is below 10 percent. My track record includes endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who provided my arXiv endorsement, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. I have built three validated platforms: IMPRINT, TOPOLOGIX for topological data analysis of drug-protein interactions with a hERG cardiotoxicity MVP, and GATE for BCI neural-stimulation safety evaluation. My technical stack spans Python with ODE/RK45 and PyMC, R, TDA tools, NEURON, AlphaFold, RDKit, and HPC pipelines. I am currently National Product Manager at Synthcare in Lagos, managing pharmaceutical product strategy across Nigeria. The Novo Nordisk Foundation's focus on health innovation, scalability, and societal impact aligns with my goal to validate the CCT model in a Nordic research environment, potentially with collaborators at the University of Copenhagen or Karolinska Institutet. The grant would fund a six-month intensive validation phase: running the Bayesian MCMC simulations at scale on HPC infrastructure, completing the review article at Neuroscience and Biobehavioral Reviews, and building a commercial prototype of IMPRINT for beta testing with two pharmaceutical partners. I am applying for MSc programmes starting October 2026 at MUG in Graz, Austria, and this grant would bridge my independent research into a formal academic pathway while establishing commercial traction. SHORT ESSAY: INNOVATION POTENTIAL The CCT model introduces a tripartite pharmacological framework that targets the conjunctive consolidation of reward and memory traces in the nucleus accumbens and hippocampus. Current addiction treatments focus on either blocking the reward signal or dampening memory retrieval, but none prevent the initial encoding of the reward-memory association. My model prevents that encoding. The formal mathematical specification, validated with ODE/RK45 solvers and Bayesian MCMC, shows that a triple combination of a dopamine D1 antagonist, a beta-adrenergic blocker, and an NMDA receptor modulator at sub-threshold doses produces super-additive effects. The encoding probability drops from 0.855 to 0.122, a reduction of 85.8 percent, with super-additivity of 12.8 percentage points beyond what any single agent or pair achieves. This is a platform technology. The same architecture can be adapted for obesity, where food-reward memories drive compulsive eating, and for gambling disorder, where cue-induced craving depends on the same neural circuits. The provisional patent covers the core architecture, not a single drug combination, allowing licensing to multiple therapeutic areas. IMPRINT, the screening tool I built, uses the CCT model to predict addiction liability of novel compounds in silico, reducing animal testing and clinical trial failure rates. TOPOLOGIX, my TDA platform, identifies off-target protein interactions that could cause cardiotoxicity, as demonstrated with the hERG MVP. Together, these tools form a computational pipeline for safer, more effective addiction therapeutics. SHORT ESSAY: FEASIBILITY AND BUDGET The project is feasible within a 12-month grant period because the core research is complete. The CCT model is specified, validated, and pre-registered. The preprints are published on OSF and Zenodo. The review article is under review at Neuroscience and Biobehavioral Reviews. What remains is scaling the Bayesian MCMC simulations to population-level inference, building the commercial prototype of IMPRINT, and establishing partnerships with Nordic research groups. The budget of 75,000 EUR would cover: 30,000 EUR for HPC compute time on a SLURM cluster to run the population dynamics simulations at 10,000 virtual patients across 100 parameter sets; 20,000 EUR for a six-month research stipend to allow full-time focus on the project; 15,000 EUR for software development of the IMPRINT prototype, including a Supabase backend and a JavaScript frontend for pharmaceutical company beta testers; 5,000 EUR for travel to Copenhagen or Stockholm to establish in-person collaboration; and 5,000 EUR for publication fees, patent maintenance, and open-access archiving. I have already built three platforms independently on a laptop in Lagos. With dedicated compute and a focused stipend, the commercial prototype and the population-level validation are achievable within the grant period. My collaborators at Michigan, Harvard, Princeton, and NYU have agreed to provide advisory input, and I have a provisional patent filing in progress. SHORT ESSAY: APPLICANT TRACK RECORD I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9, and I am a PCN-licensed pharmacist. My independent research since 2025 has produced three sole-authored preprints, one review article under review, and a co-authored paper under review at Alcohol in Elsevier. I built three validated computational platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions, and GATE for BCI neural-stimulation safety evaluation, all released under open-source licenses on GitHub. My technical skills include Python with scipy, numpy, PyMC, and ODE/RK45 solvers; R for statistical analysis; TDA with Ripser and Gudhi; NEURON and Brian2 for neural simulation; AlphaFold and RDKit for structural biology; ADMET and QSAR for pharmacokinetic prediction; GROMACS and AutoDock for molecular dynamics; and Nextflow and SLURM for HPC pipeline management. I have professional experience as National Product Manager at Synthcare, Clinical Pharmacist at Ramset Pharmacy, and Research Assistant at the Centre for Drug Discovery, Development and Production, where I performed NMDA and insulin docking studies. I also worked as a Bioinformatics Researcher with the GHRU-GSAR consortium on antimicrobial resistance genomics and surveillance pipeline development. Endorsements from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar confirm the scientific validity of my approach. My arXiv endorsement from Gershman at Harvard enabled me to submit my preprints to a rigorous preprint server. The provisional patent filing demonstrates my commitment to commercialisation. SHORT ESSAY: SOCIETAL IMPACT AND SCALABILITY Nigeria has an estimated 14.4 million people with substance use disorders, yet fewer than 10 percent have access to evidence-based treatment. Across sub-Saharan Africa, the treatment gap is wider, with most countries lacking any pharmacotherapy for opioid or alcohol use disorders. The CCT model, deployed through IMPRINT as a screening tool and as a computational service, can change this by enabling low-cost, in silico prediction of addiction liability before a drug reaches clinical trials, and by providing personalised risk assessments that guide prevention and early intervention. The scalability is built into the architecture. IMPRINT runs on a Supabase backend and can be deployed as a web application accessible from any device with an internet connection. The CCT model is drug-agnostic; it predicts addiction liability for any compound that interacts with dopamine, norepinephrine, or glutamate systems. This means it can screen libraries of thousands of compounds in hours, not months. For pharmaceutical companies developing obesity therapies, where reward-circuit dysregulation is a known side effect, IMPRINT can flag compounds that carry addiction risk before they enter Phase I trials, saving millions in development costs and preventing patient harm. The Novo Nordisk Foundation's focus on global health and scalability aligns with this vision. A partnership with a Nordic research group would allow validation of the model in European populations while the core technology is deployed in Nigeria, creating a bidirectional flow of data and expertise. The provisional patent ensures that any commercialisation generates revenue that can be reinvested into African research infrastructure. CHECKLIST - [ ] Complete online application form at grantsby.eu/grants/novo-nordisk-foundation-pioneer-innovator-grant-health-2026 - [ ] Upload motivation letter as PDF - [ ] Upload short essay on innovation potential as PDF - [ ] Upload short essay on feasibility and budget as PDF - [ ] Upload short essay on applicant track record as PDF - [ ] Upload short essay on societal impact and scalability as PDF - [ ] Upload CV including ORCID, GitHub, and publication links - [ ] Upload provisional patent filing documentation (Q3 2026) - [ ] Provide two letters of recommendation from named collaborators (Berridge, Gershman, Daw, or Mattar) - [ ] Provide proof of PCN pharmacist license - [ ] Provide degree certificate and transcript from University of Ibadan - [ ] Confirm eligibility for early-career researcher track (under 5 years since B.Pharm) - [ ] Verify deadline on programme website EDITOR NOTES - Eligibility risk: The Pioneer Innovator Grant may require affiliation with a Danish or Nordic institution. Eniola is currently an independent researcher in Lagos. Verify whether the grant accepts unaffiliated applicants or requires a host institution. If a host is required, identify a potential collaborator at University of Copenhagen or Karolinska Institutet before submission. - Fact verification: Confirm that the provisional patent is indeed filed or at least filed by Q3 2026. The profile says "provisional patent on CCT core architecture Q3 2026" which may mean it is planned, not filed. If not yet filed, adjust language to "provisional patent application in preparation." - Gap: The profile does not specify the exact grant amount or duration. The budget section assumes 75,000 EUR for 12 months. Verify the actual grant size and adjust the budget accordingly. If the grant is smaller, reduce HPC and stipend costs. If larger, add a clinical validation phase or a Nigerian pilot study. - Gap: No mention of specific Nordic collaborators by name. The strategy notes suggest University of Copenhagen or Karolinska, but no named person is in the profile. Eniola should identify and contact a potential collaborator before submission, or state that discussions are ongoing. - Gap: The profile does not include any publication in a peer-reviewed journal, only preprints and one article under review. The selection criteria require a track record of scientific excellence. Emphasise that the preprints are on OSF and Zenodo with DOIs, and that the review article is at a high-impact journal. If possible, include a letter from the journal editor confirming the review status.